Key result
COPE-BP trial evaluates pharmacist-led hypertension management in Bangladesh and Pakistan.
Why the study?
Hypertension affects over 40% of adults in South Asia, but public primary care systems are overstretched, while widely accessed community pharmacies remain under-evaluated for chronic disease care.
Does a community pharmacist-led intervention (COPE-BP) reduce systolic blood pressure in adults with hypertension in urban South Asia?
Does a community pharmacist-led intervention (COPE-BP) reduce systolic blood pressure in adults with hypertension in urban South Asia?
Answers are grounded in this paper and cite their sources.
The planned COPE-BP programme aims to determine if a context-specific, community pharmacist-led intervention is an effective and scalable strategy to improve blood pressure control among low-income urban residents in South Asia.
Hypertension is a leading contributor to cardiovascular disease in South Asia, affecting over 40% of adults, of whom most remain undiagnosed or poorly managed. Despite urgent healthcare needs, the already overstretched public primary care systems in low- and middle-income countries, particularly in rapidly growing urban areas, are falling short. Community pharmacies, often the first point of contact for low-income urban residents, represent an opportunity for delivering frontline chronic disease care. The Community-Pharmacies managing hypertension: intervention development and Evaluation in Bangladesh and Pakistan (COPE-BP) programme aims to investigate whether these widely accessed yet under-evaluated community pharmacists are effective and cost-effective, and assess whether the COPE-BP intervention can be successfully integrated into hypertension care pathways in Bangladesh and Pakistan. Beyond evaluating clinical and economic outcomes, COPE-BP seeks to reframe the role of semi-formal providers, including community pharmacies, which are key actors in primary care delivery. Through a stepwise programme encompassing intervention development, a multicentre clinical trial, implementation research, and policy engagement, COPE-BP aims to provide a scalable model for integrating non-traditional providers into national health strategies. In doing so, COPE-BP will help strengthen inclusive, people-centred health systems in LMICs.
No takes yet. Share an insight, caveat, or question.
Afaq et al. (2026) studied Hypertension (n=1,200). COPE-BP intervention vs. Standard pharmacy services and a hypertension information leaflet was evaluated on Systolic blood pressure at 24 months. The COPE-BP programme aims to evaluate the effectiveness and cost-effectiveness of a pharmacist-led hypertension management intervention in Bangladesh and Pakistan through a cluster-randomised trial.
Synapse has enriched 10 related papers. Consider them for comparative context: